- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Endo International sues Zydus Pharma to block generic version of Pfizer Chantix
United States: Endo International has sued Zydus Pharmaceuticals in Delaware federal court, claiming Zydus violated its patent rights with a generic version of Pfizer's recalled smoking-cessation drug Chantix.
Endo's generic drugmaking subsidiary Par Pharmaceutical said in a complaint made public on Wednesday that Zydus' generic infringes a newly issued U.S. patent covering Endo's process for making its version of the drug.
Endo received the patent on Tuesday, covering a method of manufacturing Chantix's active ingredient varenicline with safe levels of the impurities that caused Pfizer to take Chantix off the market. Endo asked the court to block Zydus' U.S. sales of its generic and requested an unspecified amount of money damages.
Representatives for Endo, Zydus and Pfizer did not immediately respond to requests for comment on Wednesday.
Chantix earned Pfizer more than $1 billion in sales in 2019. Pfizer recalled the drug in 2021 after finding it contained high levels of impurities that increase cancer risks.
Endo launched a generic version of the anti-smoking drug with fewer impurities later that year.
Read also: USFDA approves Zydus Varenicline Tablets for smoking addiction treatment
It said making the FDA-approved tablets is "difficult to do, as evidenced by the fact that Pfizer has been unable to reformulate its Chantix product to meet those requirements despite the huge incentive it has had to do so.
The FDA approved India-based Zydus' generic-drug application for its version of Chantix in June. Endo said Zydus has since launched the generic in the United States.
Read also: Zydus Lifesciences secures USFDA okay for Esomeprazole Magnesium for Delayed-Release Oral Suspension
The case is Par Pharmaceutical Inc v. Zydus Pharmaceuticals (USA) Inc, U.S. District Court for the District of Delaware, No. 1:23-cv-00866.
For Endo: Martin Black of Dechert
For Zydus: Not yet available
Read also: Zydus Lifesciences bags USFDA nod for Indomethacin Suppository for rheumatoid arthritis